Holen Sie sich die Stockscreener-App
5.20
2.44%
-0.13
Handel nachbörslich:
5.30
0.10
+1.92%
Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 - Bitget
Verrica Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Verrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
VRCA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VRCA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Common Warts Market: Expanding Revenue Landscape to 2034 – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Common Warts Market: Expanding Revenue Landscape To 2034 Delveinsight Nielsen Biosciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Mena FN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Fed Impact: How does Verrica Pharmaceuticals Inc score in quality rankingsEarnings Overview Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - Yahoo Finance
Watch Verrica's CEO speak live from TD Cowen's Boston healthcare conference - Stock Titan
How does Verrica Pharmaceuticals Inc. perform in inflationary periodsExit Point & Smart Allocation Stock Tips - mfd.ru
Verrica Pharmaceuticals: Strategic Execution Takes Center Stage - AD HOC NEWS
West Chester-Based Verrica Partner Launches YCANTH in Japan - MyChesCo
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer - MyChesCo
Verrica Pharmaceuticals Launches YCANTH in Japan with Torii Pharmaceutical - Intellectia AI
Verrica Pharmaceuticals appoints Chris Chapman as chief commercial officer - marketscreener.com
What’s the outlook for Verrica Pharmaceuticals Inc.’s sector2025 Year in Review & Real-Time Buy Signal Notifications - mfd.ru
Verrica Pharmaceuticals Inc. Appoints Chris Chapman as Chief Commercial Officer - marketscreener.com
Verrica Pharmaceuticals (VRCA) Appoints New Chief Commercial Off - GuruFocus
Verrica Pharmaceuticals Appoints Chris Chapman As Chief Commercial Officer - TradingView
Verrica’s Japanese Market Debut: A Strategic Expansion Unfolds - AD HOC NEWS
Verrica’s partner launches molluscum treatment in Japan By Investing.com - Investing.com Australia
Verrica’s partner launches molluscum treatment in Japan - Investing.com Nigeria
Verrica announces launch of Ycanth in Japan by Torii - The Pharma Letter
Verrica Pharmaceuticals Announces Launch Of Ycanth® For The Treatment Of Molluscum Contagiosum In Japan - TradingView
Verrica Pharmaceuticals stock rises after partner launches YCANTH in Japan - Investing.com Nigeria
Verrica Pharmaceuticals stock rises after partner launches YCANTH in Japan By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical - The Manila Times
Verrica Pharmaceuticals Announces Launch of YCANTH® for the - GlobeNewswire
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Verrica Pharmaceuticals appoints Rosenberg as CMO - MSN
ETF Watch: Can Verrica Pharmaceuticals Inc continue delivering strong returnsWeekly Trading Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Verrica Pharmaceuticals (VRCA) upgraded to strong buy: Here's why - MSN
Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why - sharewise.com
Institution Moves: What hedge funds are buying Verrica Pharmaceuticals IncTrade Exit Summary & Reliable Price Action Trade Plans - baoquankhu1.vn
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Rally Mode: What is the PEG ratio of Intellicheck Inc2025 Fundamental Recap & Smart Allocation Stock Reports - baoquankhu1.vn
Sovran Advisors LLC Trims Holdings in Verrica Pharmaceuticals Inc. $VRCA - MarketBeat
Investor Alert: Common Warts Market Set for Rapid Growth – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Portfolio Recap: How does KeyCorp perform in inflationary periodsEarnings Trend Report & AI Powered Market Trend Analysis - baoquankhu1.vn
Verrica doses first patient in phase 3 wart trial, eyes major label expansion - MSN
YCANTH Phase 3 Wart Study Puts Verrica in Focus While Veeva Extends Its Clinical Footprint - TipRanks
Verrica’s VP-102 Advances Dermatology Care: First Patient Dosed in Global Phase 3 Common Warts Program - Barchart.com
Aug PreEarnings: Is Verrica Pharmaceuticals Inc stock a value trapMarket Risk Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded to “Buy” at Wall Street Zen - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Market Fear: Is Verrica Pharmaceuticals Inc stock a value trapAnalyst Downgrade & Daily Chart Pattern Signals - baoquankhu1.vn
Trade Report: Is Verrica Pharmaceuticals Inc stock good for income investorsPortfolio Gains Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):